O. Kan

发表

Correction of the disease phenotype in the mouse model of Stargardt disease by lentiviral gene therapy

P. Gouras, R. Allikmets, J. Sparrow, 2008, Gene Therapy.

Phase I Study of MetXia-P450 Gene Therapy and Oral Cyclophosphamide for Patients with Advanced Breast Cancer or Melanoma

A. Harris, A. Makris, J. Braybrooke, 2005, Clinical Cancer Research.

Cytochrome P450-based cancer gene therapy: current status

S. Kingsman, S. Naylor, O. Kan, 2002, Expert opinion on biological therapy.

Stable and efficient intraocular gene transfer using pseudotyped EIAV lentiviral vectors

K. Balaggan, S. Naylor, K. Binley, 2006, The journal of gene medicine.

Development of photoreceptor‐specific promoters and their utility to investigate EIAV lentiviral vector mediated gene transfer to photoreceptors

P. Gouras, R. Allikmets, J. Kong, 2007, The journal of gene medicine.

EIAV vector-mediated delivery of endostatin or angiostatin inhibits angiogenesis and vascular hyperpermeability in experimental CNV

S. E. Barker, R. MacLaren, Y. Durán, 2006, Gene Therapy.

The macrophage – a novel system to deliver gene therapy to pathological hypoxia

A. Harris, P. Ratcliffe, C. Lewis, 2000, Gene Therapy.

Exploiting the hypoxia response.

S. Naylor, K. Binley, Jonathon M. White, 2003, Current opinion in molecular therapeutics.

Equine infectious anemia viral vector-mediated codelivery of endostatin and angiostatin driven by retinal pigmented epithelium-specific VMD2 promoter inhibits choroidal neovascularization.

P. Campochiaro, S. Kachi, H. Akiyama, 2009, Human gene therapy.

Direct retroviral delivery of human cytochrome P450 2B6 for gene-directed enzyme prodrug therapy of cancer

Andrew Slade, Mark Uden, M. Uden, 2001, Cancer Gene Therapy.

Genetically modified macrophages expressing hypoxia regulated cytochrome P450 and P450 reductase for the treatment of cancer.

F. Burke, S. Naylor, K. Binley, 2011, International journal of molecular medicine.